Aadi Bioscience, Inc. (NASDAQ:AADI) Given Consensus Rating of “Buy” by Brokerages

Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $43.50.

Several analysts have issued reports on AADI shares. Zacks Investment Research lowered Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, January 25th. HC Wainwright dropped their price objective on Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 11th. Finally, Piper Sandler dropped their price objective on Aadi Bioscience from $50.00 to $30.00 in a research note on Thursday, May 12th.

NASDAQ AADI traded up $0.44 during trading hours on Monday, hitting $14.79. 57,030 shares of the company traded hands, compared to its average volume of 116,821. The business’s 50-day moving average is $16.22 and its 200-day moving average is $19.70. Aadi Bioscience has a twelve month low of $11.00 and a twelve month high of $49.80.

Aadi Bioscience (NASDAQ:AADIGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.02. During the same period last year, the firm earned ($0.90) EPS. As a group, research analysts forecast that Aadi Bioscience will post -2.85 EPS for the current year.

In other Aadi Bioscience news, insider Neil Desai sold 3,550 shares of the firm’s stock in a transaction on Friday, March 18th. The stock was sold at an average price of $20.07, for a total transaction of $71,248.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.10% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in Aadi Bioscience during the 1st quarter worth $683,000. Royal Bank of Canada acquired a new stake in shares of Aadi Bioscience in the 1st quarter valued at $49,000. Goldman Sachs Group Inc. acquired a new stake in shares of Aadi Bioscience in the 1st quarter valued at $1,011,000. State Street Corp boosted its holdings in shares of Aadi Bioscience by 72.0% in the 1st quarter. State Street Corp now owns 535,578 shares of the company’s stock valued at $9,089,000 after purchasing an additional 224,178 shares in the last quarter. Finally, Eversept Partners LP acquired a new stake in shares of Aadi Bioscience in the 1st quarter valued at $2,559,000. Hedge funds and other institutional investors own 62.56% of the company’s stock.

Aadi Bioscience Company Profile (Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Further Reading

Analyst Recommendations for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.